The Australian Securities and Investments Commission has launched civil penalty proceedings against superannuation fund StatePlus over fees allegedly charged for services that were not provided to tens of thousands of members.
A court has approved a $2.9 million penalty against medical booking platform HealthEngine after the company admitted to deleting and altering unfavourable reviews and misusing consumer data.
Facebook and Google have been hit with a class action alleging their 2018 decisions to ban advertising of cryptocurrencies breached competition laws.
Google’s open letter to Australians, containing dire warnings about the effects of a proposed news media bargaining code, is misleading, the head of Australia’s consumer watchdog has said.
Consumer goods giant Procter & Gamble has dropped a lawsuit accusing competitor Colgate-Palmolive of breaching consumer laws by making false claims about the performance of its whitening toothpaste that threatened to push its own brand of whitener off the shelves.
The judge overseeing a shareholder class action against logistics provider GetSwift and three executives has vacated an upcoming trial date, following an application that he recuse himself from hearing the case.
An appeals court has been urged to uphold a judge’s $125 million penalty against Volkswagen in the ACCC’s case over the car maker’s emissions cheating, with a court-appointed contradictor saying the judge was “starved” of the information he required to assess whether a $75 million agreement brokered by the consumer watchdog was reasonable.
An error in an opt out notice sent to motorists eligible to sign up for a class action over allegedly defective diesel filters in Toyota vehicles has left a class action law firm on the hook for indemnity costs to cover a new notice to group members.
The Australian Competition and Consumer Commission has delayed it decision on whether to block Google’s $3 billion tie-up with fitness device company Fitbit to allow time for the European Union to investigate the proposed merger.
ASX-listed generic drug maker Mayne Pharma is facing a possible shareholder class action over disclosures related to US price-fixing allegations against the ASX-listed company.